Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants Clinical research trials and The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants. The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants clinical trial. Test subjects oftentimes recieve the best healthcare possible for their The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "T" Clinical Trials Conditions > The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants

The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants



The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants

For Condition: HIV Infections
Status: Terminated
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) , Abbott Laboratories,Glaxo Wellcome
Synopsis: To determine the safety and tolerance of hyperimmune anti-HIV intravenous immunoglobulin (HIVIG) and of zidovudine (AZT) in infants with established HIV infection; to get preliminary evidence for the effectiveness of this type of treatment in preventing the advance of disease in HIV infected infants. HIVIG may be an effective agent that either alone or in combination with AZT will prevent progression of clinical disease.
Details: HIVIG may be an effective agent that either alone or in combination with AZT will prevent progression of clinical disease. Participants are randomized to receive either oral AZT or HIVIG. Patients may receive treatment for a maximum of 48 weeks. Patients are evaluated during treatment at weeks 2, 4, and every 4 weeks thereafter. Infants who are receiving HIVIG initially are treated with the appropriate age-adjusted dose of oral AZT in addition to HIVIG if they meet clinical disease progression criteria. All participants who have completed 48 weeks of treatment or who are discontinued from treatment are followed every 3 months for an additional 48 weeks. This follow-up may be conducted over the telephone.
Eligibility:
Study Type:  Interventional, Treatment, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: /3 Months
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Recommended: - Standard immunizations. Should repeat MMR 3 months after discontinuing study. - Benadryl and/or aspirin. - Pneumocystis carinii pneumonia prophylaxis. - Systemic ketoconazole and acyclovir, or oral nystatin for acute therapy. - Aerosol ribavirin for short-term treatment of RSV. Concurrent Treatment: Allowed: - Blood transfusion. Patients must have the following: - Parent or guardian available to give written informed consent. - Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study. Prior Medication: Allowed: - Gammaglobulin, intravenous (IV) or intramuscular (IM). - Immunoglobulin, IV (IVIG). - Maternal antiretroviral treatment during pregnancy. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry. - Presence of serious acute infection requiring parenteral treatment at time of study entry. Concurrent Medication: Excluded: - Prophylaxis for oral candidiasis or otitis media or other infections. - Immunoglobulin therapy (except single dose or for hypogammaglobulinemia). - Ketoconazole, acyclovir, or nystatin for prophylaxis. Patients with the following are excluded: - Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry. - Presence of serious acute infection requiring parenteral treatment at time of study entry. Prior Medication: Excluded: - Antiretroviral treatment or experimental treatment within 2 weeks of entry.
Total Enrollment: 112

Location and Contact Information:

Overall Study Official:
ConnorE,  Study Chair, 


Additional Information:
Study ID Numbers:  ACTG 131; 
Study Start Date: 
Record last reviewed: March 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000961

Other Hiv Infections Studies:
1. Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS

2. Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

3. Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

4. A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus

5. Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

Related Studies:

Other HIV Infections Clinical Trials
Other Clinical Trials
Other Clinical Trials

The Safety and Effectiveness of Hyperimmune Anti-HIV Intravenous Immunoglobulin (HVIG) Plus Zidovudine in HIV-Infected Infants
Modify your Search

  Other HIV Infections Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103